Compare Freeport-McMoRan Inc (FCX) vs Mesoblast Limited (MESO) Price & Performance

FCX trades at $69.18, down 1.92% today but maintains a bullish technical outlook with strong moving average support. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.68 exceeding expectations. Revenue growth remains stable at $25.9B, while profitability metrics show improvement with net income margin expanding to 11.38%. Recent news highlights operational strength at Grasberg mine and positive copper market tailwinds.

FCX presents a compelling investment case with analyst consensus pointing to 6.8% upside to the $73.85 price target. The company's growth initiatives and copper market exposure provide tailwinds, though investors should monitor commodity price volatility and execution risks in expansion projects. With 61% of analysts rating the stock a Buy, institutional sentiment remains positive despite recent price weakness.

MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.

The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.